Table of Contents
This is a lecture that I gave early in November. I discussed the role of low-dose CT (LDCT) in lung cancer screening in a TB endemic country.
The lecture starts with a discussion of LDCT and the various trials, followed by a discussion of the new Lung-RADS 2022 and then a few cases to show how we use Lung-RADS for Category 4 lesions.
The last part of the lecture is how the presence of old and active tuberculosis (TB) lesions modulates the use of LDCT for lung cancer screening.
This post is for subscribers onlySubscribe
Already have an account? Log in